FORMULATION AND EVALUATION OF METAPROLOL SUCCINATE EXTENDED RELEASE PELLETS

Abstract

The aim and of the present study is to develop a pharmaceutically stable and quality improved formulation of Metoprolol succinate extended release pellets. To achieve this goal various prototype formulation trials were formulated and the evaluated with respect to the various quality controls such as dissolution, assay and stability studies will be under taken. Metoprolol succinate is used in the treatment of hyper tension, angina pectoris (chest pain) and myocardial infarction. The study was undertaken with an aim to formulate Metoprolol succinate extended release pellets. The optimized batch MSER CF7 is made up of 7% wetting agent and 4.5% binder. The evaluation tests that were conducted for the pellets also showed satisfactory results.The best trial was optimized by comparing the drug release profile with the innovator and the MSER F7 showed better results compared to the other formulations and the evaluation studies were conducted for the MSER F7. It showed good results in formulation of stable dose.The pellets were evaluated for the flow properties, sieve analysis and accelerated stability studies for 3months. The pellets showed good flow properties and also showed uniform size which indicates uniform coating.Finally we concluded that the Metoprolol succinate pellets MSER F7 are prepared and these showed good physico-chemical properties and the dissolution results showed satisfactory results when compared with the innovator drug.